Wailoo AJ. (2010) “Primary angioplasty in health care delivery: the economics”, in S. Brecker and M. Rothman (eds) Clinical Guide to Primary Angioplasty, InformaHealth care
Articles in refereed journals
Hernandez Alava, M., Wailoo, AJ, and Ara, R. (2012) “Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Health State Utility Values”, Value in Health. Available here.
Tosh J, Brennan A, Wailoo A, Bansback N. (2011) “The Sheffield rheumatoid arthritis health economic model”, Rheumatology, Vol.50 Suppl 4:iv26-iv31
Morden, J., Lambert, P., Latimer, N., Abrams, K., and Wailoo AJ. (2011) “Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study”, BMC Medical Research Methodology, Vol.11:4 doi:10.1186/1471-2288-11-4
Hind, D., Wailoo, AJ., Sutcliffe, P.,. (2010) Demands for “off-licence” access to Trastuzumab (Herceptin): content analysis of UK newspaper articles, Health Expectations, doi: 10.1111/j.1369-7625.2010.00617.
Lloyd, S., Bujkiewicz, S., Wailoo, AJ., Sutton, AJ., Scott, DI. (2010) the effectiveness of anti-tnf alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta analysis, Rheumatology, 49(12):2313-2321
Tosh, J., Wailoo, AJ., Scott, D, Deighton, C. (2011) “Cost-effectiveness of combination non-biologic disease modifying anti rheumatic drug strategies in patients with early RA”, Journal of Rheumatology, Vol.38: 1593-1600
Wailoo AJ, Goodacre S, Sampson F, Hernandez Alava M, et al. (2010) Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction in the UK NHS: an economic analysis of the National Infarct Angioplasty Project Pilots. Heart, 96:668-672
Wailoo AJ, Tsuchiya A, McCabe C. (2009) Weighting must wait: incorporating equity concerns into cost effectiveness analysis may take longer than expected. Pharmacoeconomics, Vol.27(12):983-989.
Wailoo AJ, Sutton A, Morgan A. (2009) The risk of febrile neutropenia in patients with non small cell lung cancer treated with docetaxel: a systematic review and meta-analysis, British Journal of Cancer, Vol.100(3):436-441
Goodacre S, Sampson F, Carter A, Wailoo A, et al. (2008) Evaluation of the National Infarct Angioplasty Project. NHS SDO final report
Oluboyede Y, Goodacre S, Wailoo A. (2008) Cost effectiveness of chest pain unit care in the NHS. BMC Health Services Research, vol.8:174
Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon R, Wolfe F. (2008) Biologic Drugs for Rheumatoid Arthritis in the Medicare Program: A Cost Effectiveness Analysis. Arthritis and Rheumatism, Vol. 58(4):939-946.
Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KA, Brennan A, Nicholson KG. (2008) “Cost - effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.” Value in Health, Vol.11(2):160-171.
Wailoo A, Bansback N, Chilcott J. (2008) Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Editorial, Rheumatology, Vol.47:119–120
Cheater F, Baker R, Gillies C, Wailoo A, Spiers N, Reddish S, et al. (2008) “The nature and impact of urinary incontinence experienced by patients receiving community nursing services: A cross-sectional cohort study”, International Journal of Nursing Studies, Vol. 45:339-351.
Dolan P, Edlin R, Tsuchiya A, Wailoo A. (2007) “It ain’t what you do, it’s the way that you do it: characteristics of procedural justice and their importance in social decision-making, Journal of Economic Behavior and Organization, Vol.64: 157-70
Connock, M., Burls, A., Frew, E., Fry-Smith, A., Juarez-Garcia, A., McCabe, C., Wailoo, A., O’Hagan, A., et al. (2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease, Health Technology Assessment, Vol.10 (24)
Wailoo, A., Bansback, N., Brennan, A., Nixon, R., Michaud, K., Wolfe, F. (2006) Modeling the Cost Effectiveness of Etanercept, Adalimumab and Anakinra Compared to Infliximab in the Treatment of Patients with Rheumatoid Arthritis in the Medicare Program. Agency for Healthcare Research and Quality. Technology Assessment Program. Available at http://www.cms.hhs.gov/DemoProjectsEvalRpts/downloads/MMA641_Rheumatoid_Arthritis.pdf
Turner, DA, Wailoo A, Nicholson KG, Cooper NJ, Sutton AJ, Abrams KR. (2006) “The cost-effectiveness of influenza vaccination of healthy adults 50 to 64 years of age.” Vaccine, Vol.24:1035-43.
Goodacre, S., Stevenson, M., Wailoo, A., Sampson, F., Sutton, A., Thomas, S. (2006) How should we diagnose suspected deep vein thrombosis, Quarterly Journal of Medicine, Vol.99(6):377-88.
Goodacre, S., Sampson, F., Stevenson, M., Wailoo, A., Sutton, A. et al. (2006) “Measurement of the clinical and cost effectiveness of non invasive diagnostic testing strategies for deep vein thrombosis.” Health Technology Assessment, Vol.168(15).
Cheater, F., Baker, R., Reddish, S., Spiers, N., Wailoo, A., Gillies, C., Robertson, N., Cawood, K. (2006) Cluster Randomised Controlled Trial of the Effectiveness of Audit and Feedback and Educational Outreach on Improving Nursing Practice and Patient Outcomes, Medical Care, Vol.44(6):542-551
Wailoo, A. and Anand, P. (2005) “The nature of Procedural Preferences for health-care Rationing Decisions”. Social Science and Medicine, Vol.60(2): 223-236.
Aki Tsuchiya; Luis S Miguel; Richard Edlin; Allan Wailoo; Paul Dolan (2005) “Procedural justice in public health care resource allocation”, Journal of Applied Health Economics and Policy, Vol.4(2):119-128
R. D. Riley, S. A. Burchill, K. R. Abrams, D. Heney, A. J. Sutton, D. R. Jones, P. C. Lambert, B. Young, A. J. Wailoo and I. J. Lewis. (2004) “A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma” Clinical Cancer Research, Vol.10:4-12.
Cooper, N., Sutton, A., Abrams, K., Turner, D., and Wailoo, A. (2004) "Comprehensive decision analytical modelling in economic evaluation: A Bayesian approach", Health Economics, Vol.13(3).
R. D. Riley, S. A. Burchill, K. R. Abrams, D. Heney, A. J. Sutton, D. R. Jones, P. C. Lambert, B. Young, A. J. Wailoo and I. J. Lewis. (2003) "A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family", European Journal of Cancer, Vol.39(1):19-30.
David Turner, Allan Wailoo, Karl Nicholson, Nicola Cooper, Alexander Sutton, Keith Abrams. (2003) "Systematic review and economic decision modelling for the prevention and treatment of influenza A and B”, Health Technology Assessment Report, Vol.7.No.35.
Riley, RD., Burchill, SA., Abrams, KA., Heney, D., Lambert, PC., Jones, DR., Sutton, AJ., Young, B., Wailoo, AJ, Lewis, IJ. (2003) “A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and neuroblastoma”, Health Technology Assessment, Vol. 7: No. 5
Cooper, N., Sutton, A., Abrams, K., Wailoo, A., Turner, D., and Nicholson, K.G. (2003) “Effectiveness of neuraminidase inhibitors in the treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials” BMJ, Vol.326(7401):1235-1242
Shields, M., and Wailoo, A. (2001) " Exploring The Determinants Of Unhappiness For Ethnic Minority Men In Britain", Scottish Journal of Political Economy, Vol. 49(4):445-466.
Anand, P. and Wailoo, A. (2000) “Utilities versus Rights for Publicly Provided Goods: Arguments and Evidence from Health Care Rationing”, Economica, Vol.67(268):543-577.
Letters
Wailoo AJ, Bansback N, Chilcott J. (2008) Comment on Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply. Rheumatology, vol.47 (10):1590.
Dolan, P., Tsuchiya, A., Wailoo, A. (2003), The NICE Citizen’s Council: What do we ask them, and how? The Lancet, 362 (9387):918-9